<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 8)
COPLEY PHARMACEUTICAL, INC.
-------------------------------------
(Name of Issuer)
Common Stock, par value $.01 per share
-------------------------------------
(Title of Class of Securities)
21745K-10-1
---------------------
(CUSIP Number)
David A. Jenkins
President
Celanese Americas Corporation
(formerly Hoechst Corporation)
86 Morris avenue
Summit, NJ 07901
(908) 231-4058
-------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
August 17, 1999
---------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
[_].
<PAGE>
This Amendment to the Statement on Schedule 13D (the "Schedule 13D")
with respect to the Common Stock of Copley Pharmaceutical, Inc. (the "Issuer")
is filed by Celanese Americas Corporation (formerly Hoechst Corporation), a
Delaware corporation ("Parent").
Item 2. Identity and Background.
Celanese Americas Corporation
Delaware
Holding Company
30 Independence Boulevard
Warren, New Jersey 07059
Effective August 17, 1999, Hoechst Corporation, a Delaware
corporation, changed its name to Celanese Americas Corporation.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: August 19, 1999
CELANESE AMERICAS CORPORATION
By: /s/ David A. Jenkins
-----------------------------------
Name: David A. Jenkins
Title: President
